Posted by Michael Wonder on 16 Aug 2018
SMA groups outraged over UK rejection of Spinraza coverage as too expensive
16 August 2018 - Devastating. Heartbreaking. A death sentence for an estimated 1,000 children with spinal muscular atrophy (SMA).
These are among the many angry reactions to Tuesday’s appraisal consultation document issued by a committee of Britain’s independent, government-funded National Institute of Health and Care Excellence (NICE).
That opinion recommends against Spinraza (nusinersen), an approved SMA treatment, being added to the subsidised public health system of England and Wales because of its “extremely high cost.”
